CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
Clinical trial NCT02259556 · RECRUITING
Trial details
- NCT number
- NCT02259556
- Sponsor
- Chinese PLA General Hospital
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-10-01
- Primary completion
- 2018-10-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.